LT3830092T - Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai - Google Patents

Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai

Info

Publication number
LT3830092T
LT3830092T LTEPPCT/US2019/044814T LTUS2019044814T LT3830092T LT 3830092 T LT3830092 T LT 3830092T LT US2019044814 T LTUS2019044814 T LT US2019044814T LT 3830092 T LT3830092 T LT 3830092T
Authority
LT
Lithuania
Prior art keywords
heteroaromatic
nmda receptor
receptor modulators
nmda
modulators
Prior art date
Application number
LTEPPCT/US2019/044814T
Other languages
English (en)
Inventor
Robert Volkmann
David Anderson
Sam Malekiani
Timothy Piser
Gregg KEANEY
Steven LEISER
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3830092T publication Critical patent/LT3830092T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEPPCT/US2019/044814T 2018-08-03 2019-08-02 Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai LT3830092T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862714100P 2018-08-03 2018-08-03
PCT/US2019/044814 WO2020086136A2 (en) 2018-08-03 2019-08-02 Heteroaromatic nmda receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
LT3830092T true LT3830092T (lt) 2023-09-11

Family

ID=69228330

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/044814T LT3830092T (lt) 2018-08-03 2019-08-02 Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai

Country Status (37)

Country Link
US (5) US10584131B2 (lt)
EP (2) EP4223760A1 (lt)
JP (1) JP7319369B2 (lt)
KR (1) KR20210039432A (lt)
CN (1) CN112513047B (lt)
AR (1) AR115905A1 (lt)
AU (1) AU2019368147B2 (lt)
BR (1) BR112021001967A2 (lt)
CA (1) CA3108519A1 (lt)
CL (1) CL2021000294A1 (lt)
CO (1) CO2021002898A2 (lt)
CR (1) CR20210125A (lt)
CU (1) CU24647B1 (lt)
CY (1) CY1126144T1 (lt)
DK (1) DK3830092T3 (lt)
DO (1) DOP2021000025A (lt)
EA (1) EA202190431A1 (lt)
EC (1) ECSP21014902A (lt)
ES (1) ES2951872T3 (lt)
FI (1) FI3830092T3 (lt)
HR (1) HRP20230774T1 (lt)
HU (1) HUE062566T2 (lt)
IL (1) IL280474B2 (lt)
JO (1) JOP20210020A1 (lt)
LT (1) LT3830092T (lt)
MA (1) MA53351B1 (lt)
MX (1) MX2021001367A (lt)
PE (1) PE20210948A1 (lt)
PH (1) PH12021550242A1 (lt)
PL (1) PL3830092T3 (lt)
PT (1) PT3830092T (lt)
RS (1) RS64359B1 (lt)
SG (1) SG11202101125VA (lt)
SI (1) SI3830092T1 (lt)
TW (1) TWI833783B (lt)
WO (1) WO2020086136A2 (lt)
ZA (1) ZA202101273B (lt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3386990B1 (en) 2015-12-09 2023-04-19 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
SMT202000534T1 (it) * 2015-12-09 2020-11-10 Cadent Therapeutics Inc Modulatori eteroaromatici del recettore nmda e loro usi
WO2018119374A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics Nmda receptor modulators and uses thereof
LT3830092T (lt) 2018-08-03 2023-09-11 Novartis Ag Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai
WO2025019109A1 (en) * 2023-07-17 2025-01-23 Neumora Therapeutics, Inc. Modulators of nmda receptors and related products and methods

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358891A1 (fr) 1976-07-22 1978-02-17 Yamanouchi Pharma Co Ltd Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires
FR2549834B1 (fr) 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
US4921854A (en) 1986-12-30 1990-05-01 Egis Gyogyszergyar Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds
US5298502A (en) 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
WO1994027975A1 (de) 1993-05-21 1994-12-08 Pentapharm Ag 3-(mercaptoalkyl)- bzw. 3-(alkylthioalkyl)-pyrimidin-2,4 (1h, 3h)-dione
AU719102B2 (en) 1996-06-28 2000-05-04 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
WO2002000629A1 (en) 2000-06-26 2002-01-03 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
MX2007000468A (es) 2004-07-13 2007-03-08 Hoffmann La Roche Derivados de sulfonamida.
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
CA2663161C (en) 2006-09-11 2014-10-28 N.V. Organon Quinazolinone and isoquinolinone acetamide derivatives
WO2008033757A2 (en) 2006-09-11 2008-03-20 N.V. Organon 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
AU2007333925B2 (en) 2006-12-15 2013-10-31 Nantbio, Inc. Triazine derivatives and their therapeutical applications
EP1939187A1 (en) 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
US8183276B2 (en) 2007-02-08 2012-05-22 Christian Fischer Therapeutic agents
WO2008128982A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors
CA2685753A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
JP5313246B2 (ja) 2007-08-21 2013-10-09 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としてのヘテロシクリル化合物
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
ES2586459T3 (es) 2008-05-01 2016-10-14 Glaxosmithkline Llc Quinolinas y análogos relacionados como moduladores de sirtuina
CA2726262A1 (en) 2008-05-29 2009-12-03 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
US8846947B2 (en) 2008-07-03 2014-09-30 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
CN102227420B (zh) 2008-09-29 2015-06-24 西特里斯药业公司 作为沉默调节蛋白调节剂的喹唑啉酮、喹诺酮和相关的类似物
CA2747419C (en) 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
ES2540119T3 (es) 2009-03-27 2015-07-08 Abbvie Inc. Compuestos como ligandos de receptores cannabinoides
EP2264035A1 (en) 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
IN2012DN02968A (lt) 2009-10-13 2015-07-31 Msd Oss Bv
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
EP2593106A4 (en) 2010-07-16 2014-01-01 Univ Rockefeller ORGANIC CONNECTIONS
WO2012052540A1 (en) 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
US20120165330A1 (en) 2010-12-22 2012-06-28 Sirtris Pharmaceuticals, Inc. Quinazolinone and related analogs as sirtuin modulators
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
ES2785475T3 (es) 2011-05-10 2020-10-07 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores de canales iónicos
US9493412B2 (en) 2011-09-27 2016-11-15 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
EP2760840B1 (en) 2011-09-30 2015-08-12 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
EP2760839B1 (en) 2011-09-30 2015-11-25 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
CN102336768A (zh) 2011-10-24 2012-02-01 中国科学院上海有机化学研究所 N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途
CN109970760B (zh) 2011-11-11 2022-04-26 吉利德阿波罗公司 Acc抑制剂和其用途
CN108299314B (zh) 2012-02-10 2024-11-26 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
BR112015032539B1 (pt) 2013-06-28 2022-07-12 Beigene, Ltd Compostos ureia tricíclicos fundidos como inibidores de raf cinase e/ou dímero de raf cinase e composição farmacêutica compreendendo os referidos compostos
WO2015007453A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
US20150141433A1 (en) 2013-09-26 2015-05-21 Mnemosyne Pharmaceuticals, Inc. N-arylmethyl sulfonamide negative modulators of nr2a
BR112016007563B1 (pt) 2013-10-11 2022-12-20 F. Hoffmann-La Roche Ag Tiazolopirimidinonas, seus usos, e composição farmacêutica
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
CN103664877A (zh) 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
EP3191459A1 (en) 2014-09-05 2017-07-19 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US12006328B2 (en) 2014-11-18 2024-06-11 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto
KR20170137137A (ko) 2015-04-15 2017-12-12 에프. 호프만-라 로슈 아게 피리도피리미딘온 및 nmda 수용체 조절인자로서 그의 용도
JP2018530593A (ja) 2015-10-16 2018-10-18 ノースウェスタン ユニバーシティ 統合失調症、双極性障害、認知障害及び大うつ病性障害の治療のための非定型的抗精神病薬ならびにｎｍｄａ調節剤の医薬品の組み合わせ
EP3386990B1 (en) 2015-12-09 2023-04-19 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
SMT202000534T1 (it) * 2015-12-09 2020-11-10 Cadent Therapeutics Inc Modulatori eteroaromatici del recettore nmda e loro usi
WO2017188694A1 (ko) 2016-04-25 2017-11-02 이뮤노메트테라퓨틱스 인코포레이티드 질소를 포함하는 헤테로아릴 화합물 및 이의 용도
US11186564B2 (en) 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
WO2018119374A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics Nmda receptor modulators and uses thereof
GEP20227429B (en) 2017-09-27 2022-10-25 Incyte Corp Salts of pyrrolotriazine derivatives useful as tam inhibitors
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
LT3830092T (lt) 2018-08-03 2023-09-11 Novartis Ag Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai

Also Published As

Publication number Publication date
SI3830092T1 (sl) 2023-09-29
TW202019932A (zh) 2020-06-01
MA53351B1 (fr) 2023-08-31
PE20210948A1 (es) 2021-05-24
AU2019368147B2 (en) 2024-05-30
TWI833783B (zh) 2024-03-01
CO2021002898A2 (es) 2021-05-31
KR20210039432A (ko) 2021-04-09
FI3830092T3 (fi) 2023-07-21
US11542264B2 (en) 2023-01-03
US20210403474A1 (en) 2021-12-30
CU20210013A7 (es) 2021-09-07
US20240199617A1 (en) 2024-06-20
HRP20230774T1 (hr) 2023-10-27
WO2020086136A2 (en) 2020-04-30
CL2021000294A1 (es) 2021-06-18
EA202190431A1 (ru) 2021-06-11
PH12021550242A1 (en) 2021-11-29
AR115905A1 (es) 2021-03-10
RS64359B1 (sr) 2023-08-31
US10584131B2 (en) 2020-03-10
DOP2021000025A (es) 2021-05-31
JOP20210020A1 (ar) 2021-01-25
DK3830092T3 (en) 2023-08-07
EP4223760A1 (en) 2023-08-09
CY1126144T1 (el) 2023-11-15
MA53351A (fr) 2022-01-12
HUE062566T2 (hu) 2023-11-28
JP2021534227A (ja) 2021-12-09
ES2951872T3 (es) 2023-10-25
PL3830092T3 (pl) 2023-11-13
EP3830092A2 (en) 2021-06-09
AU2019368147A1 (en) 2021-03-18
US20250034145A1 (en) 2025-01-30
CN112513047B (zh) 2023-10-20
CN112513047A (zh) 2021-03-16
ZA202101273B (en) 2023-05-31
IL280474A (en) 2021-03-01
EP3830092B1 (en) 2023-05-03
CA3108519A1 (en) 2020-04-30
PT3830092T (pt) 2023-07-25
SG11202101125VA (en) 2021-03-30
IL280474B1 (en) 2023-05-01
CU24647B1 (es) 2023-02-13
IL280474B2 (en) 2023-09-01
US20200039987A1 (en) 2020-02-06
CR20210125A (es) 2021-06-30
ECSP21014902A (es) 2021-05-31
MX2021001367A (es) 2021-06-23
WO2020086136A3 (en) 2020-08-06
US20200131190A1 (en) 2020-04-30
BR112021001967A2 (pt) 2021-04-27
US10752633B2 (en) 2020-08-25
JP7319369B2 (ja) 2023-08-01

Similar Documents

Publication Publication Date Title
ZA201807731B (en) Spiro-lactam nmda receptor modulators and uses thereof
LT3626825T (lt) Anti-cdh6 antikūnas bei anti-cdh6 antikūno ir vaisto konjugatas
EP3746447C0 (en) SPIRO-LACTAM MODULATORS OF NMDA RECEPTORS AND THEIR USE
IL276330A (en) Spiro-lactam NMDA receptor modulators and their use
IL264514A (en) Spiro-lactam modulates and uses of the nmda receptor
LT3830092T (lt) Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai
IL264488A (en) Spiro-lactam nmda receptor modulators and uses thereof
IL286107A (en) Spiro-lactam nmda receptor modulators and uses thereof
LT3484865T (lt) Somatostatino moduliatoriai ir jų panaudojimas
HK1255160A1 (zh) 取代的4-氮雜吲哚以及它們作為glun2b受體調節劑的用途
EP3490994B8 (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
IL288858A (en) Transmuted heteroaromatic pyrazolopyridines and their use as glun2b receptor modulators
EP3558318A4 (en) NMDA RECEIVER MODULATORS AND USES OF THEM
DK3386591T3 (da) Heteroaromatic nmda receptor modulators and uses thereof
EP3644602A4 (en) IMAGING ELEMENT, LAMINATE IMAGING ELEMENT AND SEMICONDUCTOR IMAGING DEVICE
EP3374386C0 (en) PROTEASE-ACTIVATED RECEPTOR TYPE 2 MODULATORS
DK3581572T3 (da) Adenosin-A3-receptormodulatorer
IL269213A (en) Antigen receptors and uses thereof
EP3583090A4 (en) PROLINE-BASED NEUROPEPTIDE FF RECEIVER MODULATORS
EP3744738A4 (en) CHEMERICAL ANTIGENIC RECEPTOR AND RELATED APPLICATION